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Background: Pulmonary tuberculosis (PTB) is associated with many forms of chronic lung
disease including the development of chronic airflow obstruction (AFO). However, the
nature, evolution and mechanisms responsible for the AFO after PTB are poorly understood.
The aim of this study was to examine the progression of changes in lung physiology in
patients treated for PTB.
Methods: Immunocompetent, previously healthy, adult patients receiving ambulatory treat-
ment for a first episode of tuberculosis were prospectively followed up with serial lung
physiology and quantitative computed tomography (CT) lung scans performed at diagnosis
of tuberculosis, 2, 6, 12 and 18 months during and after the completion of treatment.
Results: Forty-nine patients (median age 26 years; 37.2% males) were included, and 43
were studied. During treatment, lung volumes improved and CT fibrosis scores decreased,
but features of AFO and gas trapping emerged, while reduced diffusing capacity (DLco) seen
in a majority of patients persisted. Significant increases in total lung capacity (TLC) by
plethysmography were seen in the year following treatment completion (median change
5.9% pred., P<0.01) and were driven by large increases in residual volume (RV) (median
change +19%pred., P<0.01) but not inspiratory capacity (IC; P=0.41). The change in RV/
TLC correlated with significant progression of radiological gas trapping after treatment
(P=0.04) but not with emphysema scores. One year after completing treatment, 18.6% of
patients had residual restriction (total lung capacity, TLC <80%pred), 16.3% had AFO,
32.6% had gas trapping (RV/TLC>45%), and 78.6% had reduced DLco.
Conclusion: Simple spirometry alone does not fully reveal the residual respiratory impair-
ments resulting after a first episode of PTB. Changes in physiology evolve after treatment
completion, and these findings when taken together, suggest emergence of gas trapping after
treatment likely caused by progression of small airway pathology during the healing process.
Keywords: tuberculosis, post-tuberculosis, chronic obstructive pulmonary disease, lung
function, computed tomography, airflow obstruction
Plain Language Summary
Pulmonary tuberculosis is known to cause permanent damage to the lungs in some indivi-
duals. This study shows that in previously healthy, young (median age of 26 years),
immunocompetent adults, routine spirometry underestimates the amount of residual damage
after a first episode of tuberculosis, when more specialized physiology tests are also used to
assess patients. More importantly, it shows that changes to the lung occur even after
treatment completion. In the year after finishing treatment, there were significant increases
in lung volumes, and these increases were largely due to increases in residual volume (the
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volume remaining in the lung after full expiration). This physio-
logical change implies that after treatment completion gas trap-
ping may emerge. This was confirmed on CT scanning of the
lung in a subset of patients where physiological changes corre-
lated significantly with imaging changes of gas trapping. When
taken together, this physiological-radiological comparison sug-
gests that after tuberculosis, changes may occur to the small
airways, likely narrowing, resulting in the development of gas
trapping and airflow obstruction.
Introduction
Pulmonary tuberculosis (PTB) may cause permanent
impairment of lung function and is associated with sev-
eral forms of chronic lung disease.1–8 An association
between past PTB and chronic airflow obstruction
(AFO) has been reported in large population-based epi-
demiological studies3–6 and contributes to the heavy bur-
den of chronic airways disease seen in high PTB
prevalence communities. A causal relationship is sug-
gested by studies examining changes in lung function in
patients completing PTB.7,9–13 There is, however, little
published evidence for the mechanisms responsible for
the impairment of lung function and its clinical course.
A common assumption is that the more striking and
characteristic sequelae of PTB, namely bronchiectasis,
fibrosis, and bronchial stenosis are the major mechanisms
responsible for AFO,2,3,14 but few studies have attempted
a more thorough assessment of regional structure–func-
tion relationships within affected lungs. Nor has it been
established whether lung function impairment progresses
after the active TB infection has been successfully treated.
In a previous observational study of patients with a past
history of PTB and spirometric evidence of AFO, we have
confirmed that static gas trapping and reduced diffusing
capacity (DLco) are common findings, and we have
hypothesized that this is best explained by widespread
cicatricial changes in or surrounding bronchovascular
bundles containing small airways.15 Further, this process
may progress over time and contribute to chronic airflow
obstruction seen later after treatment has been completed.
This observation raises the possibility of considering
interventions that might limit these late effects of PTB.
We report here the results of a prospective study of the
serial changes in lung function and quantitative CT find-
ings in a cohort of patients with active PTB treated for six
months and followed for one year after completion of
treatment for PTB, and describe the nature and course of




Patients with newly diagnosed drug-sensitive pulmonary TB
were recruited from two local ambulatory TB clinics.
Eligible patients gave written consent, were 18 years or
older with active PTB diagnosed on sputum nucleic acid-
amplification testing, confirmed by microscopy and culture.
Patients were required to be HIV negative or HIV positive
with a CD4 count of over 250 cell/μL. Exclusion criteria
were a history of previous PTB, known chronic lung disease
or malignancy; a history of illicit drug use; pregnant at the
time of diagnosis; or a diagnosis of drug-resistant tuberculo-
sis. Consecutive patients meeting enrollment criteria on
recruitment days were invited to participate, with
a maximum of three patients recruited per day. For inclusion
in the analysis, patients were required to complete an out-
patient course of standard anti-tuberculosis therapy (6
months).
Study Protocol
Enrolled patients attended for five study visits: On the day
of PTB diagnosis (Visit 1), and at 2, 6, 12 and 18 months
thereafter (Visits 2 to 5, respectively). At each visit, sub-
jects performed a six-minute walk test, and spirometry
before and after administration of an inhaled bronchodila-
tor salbutamol 200ug from a pressurized metered-dose
inhaler (pMDI), according to ATS/ERS standards, and16
Global Lung Initiative (GLI) reference equations were
used. Body plethysmography and diffusing capacity for
carbon monoxide (DLco) corrected for hemoglobin, were
performed at 2, 6 and 18 months, and the St. George’s
Respiratory Questionnaire (SGRQ) at 6 and 18 months.
Plethysmography and DLco were not performed prior to 2
months to reduce the risk of infection to staff.
Chronic obstructive pulmonary disease is currently
defined by the presence of airflow obstruction identified
by having FEV1/FVC <0.70,17 however, this may under-
estimate disease in younger persons. Airflow obstruction
was defined as a post-bronchodilator ratio of forced
expiratory volume in 1 sec (FEV1) to forced vital capacity
(FVC) (ie, FEV1/FVC) of less than the predicted lower
limit of normal (LLN). Restriction was defined as total
lung capacity (TLC) less than 80% predicted, and gas
trapping on plethysmography was defined as a residual
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volume (RV) to TLC ratio (RV/TLC) of greater than 45%.
A low DLco (corrected for hemoglobin) and DLco with
alveolar volume (VA) correction (ie, DLco/VA) were
defined as values of less than 80% predicted.
All patients underwent three high-resolution computed
tomography (HRCT) scans of the chest, using a low-dose,
non-contrasted protocol that included both inspiratory and
expiratory scans. Patients were randomized (1:1:2) into
three groups. Group 1 had HRCT scans at Visit 1 (base-
line) and after 2 weeks and one month of treatment, Group
2 had scans at baseline, 1 and 2 months, and Group 3 had
scans at 2 (Visit 2), 6 (Visit 3) and 18 months (Visit 5).
CT scan images were analyzed quantitatively using in-
house software (Los Angeles, USA).18 Using inspiratory
scans (ie, TLC scans), percentages of low-attenuation
areas (LAAs) <–950 HU were used to define emphysema,
and fibrosis was measured as the quantity of lung fibrosis
(QLF) of high-attenuation areas (HAAs) >200 HU, either
as a percentage (QLF (%)) or millilitre volume (QLF
(mL)). On the expiratory scans (ie, RV scans), the percen-
tage of LAAs <–856 HU on expiratory (RV) scans was
used to calculate the gas-trapping score (GTS).
This study was conducted in accordance with the
Declaration of Helsinki, patient consent was written
informed consent and ethical approval for the study was
obtained from the University of Cape Town Human Ethics
Committee (REF: 248/2013).
Statistical analysis was performed in the statistical
programming language R version 3.4.1 (www.r-project.
org/) and STATA version 12 (StataCorp, Texas, USA).
Descriptive statistics are reported as means and standard
deviations when variables are approximately normally
distributed and as medians and interquartile ranges when
not. Testing for significant differences was done using the
Wilcoxon Signed-Rank test for paired data that was not
normally distributed. For the difference testing, no correc-
tion for multiplicity was applied (38 comparisons were
made). Simple linear regression was used for correlations
between lung function and radiological variables.
Sensitivity analysis for the influence of outliers on the
regression was performed, and alpha for all tests was set
at 0.05.
Results
A total of 49 patients were recruited. Six patients were
excluded from the long-term outcome analysis (see
Figure 1). For the remaining 43 subjects, 16 (37.2%) were
male, median age of 26 years and 31 (72.1%) were aged 40
years or less. Baseline characteristics and smoking status are
reported in Table 1. The mean time to Visits 2, 3 and Visit 5
were 8.1 weeks, 26.3 weeks and 81.1 weeks, respectively.
Four subjects delayed Visit 5 due to pregnancy (all conceived
after treatment completion).
Physiological Changes Over Time (Table 2)
Between baseline and 6 months values for FEV1, FVC but
not for FEV1/FVC increased. The majority of the improve-
ments occurred in the first two months of treatment for
both FEV1 (median change = 4.6% pred., P<0.01) and
FVC (median change = 4.5% pred., P<0.01). Smaller,
but statistically significant changes were also observed
between 2 and 6 months for FEV1 (median change =
2.9%pred., P<0.01) and FVC (median change = 4.9%







Visit 2 (2 months)
Visit 3 (6 months)
Visit 4 (12 months)
Visit 5 (18 months)
1 Patient - died of cancer (excluded)
1 Patient – imprisoned (excluded)
1 Patient – diagnosed with MDR TB (excluded)
2 Patients - retreated for TB (excluded)
1 Patient  - Lost to follow-up: (partly excluded: no 
Plethysmography  or Dlco).
Figure 1 Recruitment and exclusion of subjects.
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6 months and 18months (Visit 5), there were additional
significant increases in FEV1 (median change = 3.5%pred.,
P<0.01), FVC (median change = 3.5%pred., P=0.07) and
a non-significant increase in FEV1/FVC (P=0.25).
On plethysmography (Figure 2), there was a small but
significant increase in TLC and FRC between 2 months and 6
months (median change 3.5% of pred. (P=0.02); and median
change 2.3% of pred. (P=0.05), respectively), but non-
significant increases in RV (P=0.35). Between 6 and 18 months
(ie, after treatment completion), a statistically significant
increase in TLC (median change 5.9% pred., P<0.01), RV
(median change 19.4% of pred., P<0.01) and FRC (median
change 9.3% pred. P<0.01) was observed. There was no sig-
nificant change in IC between 2 and 6months, or between 6 and
18 months (P=0.55 and P=0.41, respectively) (see Table 2).
The DLco (%pred.) did not change significantly
between 2 and 6months (P=0.18), or between 6 and 18
months (P=0.07).
The six-minute walk distance did not improve signifi-
cantly at two months (median change 15 m, P=0.06), or
thereafter. A statistically significant but not clinically impor-
tant decrease (improvement) in SGRQ total score was
observed between 6 and 18 months (−1.0 units, P<0.01).
One year after completion of treatment (ie, Visit 5),
seven patients (16.3%) had AFO, and in six (14.0%) FEV1
/FVC was <0.70. Gas trapping was found in 14 (32.6%),
and restriction in eight (18.6%) patients. DLco was
reduced in 33 of 42 patients (78.6%), and DLco/VA was
reduced in 14 of 42 patients (33.3%). The combinations of
AFO, restriction, gas trapping and reduced DLco are
shown in Figure 3.
Changes in Quantitative Imaging Over
Time (Table 3)
On CT imaging the TLC increased significantly between 2
and 6 months (median change 0.22L, P=0.01), but not
between 6 and 18 months (P=0.99).
The median gas-trapping scores (ie, <-856HU on RV
scan) measured at 2 and 6 months were not significantly
different (P=0.19), but showed small but significant
increases between 6 and 18 months (P=0.04). The median
difference in emphysema score (ie, LAA<-950HU)
between 2 and 6 months and between 6 and 18 months
were non-significant (0.92%, P=0.20 and 0.90%, P=0.11,
respectively). The median fibrosis score decreased signifi-
cantly between 2 and 6 months (P<0.01), but changes
between 6 and 18 months were non-significant (P=0.07).
At 18 months, 14 of 19 (73.7%) patients had >5% GTS
on expiratory CT scan, seven of whom (36.8%) had a GTS
value >10%, and two (10.5%) GTS>20%. Fibrosis scores,
and radiological volumes are reported in Table 3.
Correlation Between Physiologic and
Radiologic Measures Over Time
The overall change in RV/TLC (measured by plethysmo-
graphy) between 2 and 18 months correlated with changes
in radiological GTS (R2= 0.23, P=0.04). This correlation
was observed only after 6 months (R2=0.36, P=0.01), and
not at earlier time points (P=0.90). By contrast, the corre-
lation between change in RV/TLC (plethysmography) and
change in LAA between 2 and 18 months was not sig-
nificant (R2=0.19, P=0.052). The change in FEV1/FVC
between 2 and 18 months correlated poorly with change
in radiological GTS (R2= 0.10, P=0.18), and with change
in LAA (emphysema score; P=0.11).
Table 1 Baseline Demographic and Spirometric Characteristics
Population Characteristics Number (% of
Patients)
(n=43)
Male – n (%) 16 (37.2%)
Age – years, median (range) 26 (20 to 65)
Race
African – n (%) 10 (23.3%)
Mixed race – n (%) 33 (76.7%)
Smoking Status
Never smokers – n (%) 12 (27.9%)
Former-smokers – n (%) 11 (25.6%)
Current smokers – n (%) 20 (46.5%)
Pack years for ever smokers – median
(IQR)
3.0 (1.4–8.1)
HIV positive – n (%) 2 (4.7%)
Baseline Spirometry (Post-Bd)
Median (IQR)
FEV1 (L) 1.97 (1.50 to 2.76)
FEV1 (%pred.) 0.59 (0.50 to 0.77)
FVC (L) 2.49 (1.90 to 3.02)
FVC (%pred.) 0.63 (0.54 to 0.73)
FEV1/FVC (%) 81.9 (75.2 to 88.1)
FEV1/FVC< LLN 9 (20.9%)
FEV1/FVC< 0.70 5 (11.6%)
Abbreviations: SD, standard deviation; FEV1, forced vital capacity in 1 sec; FVC,
forced vital capacity; %pred., percentage of predicted value; L, litres; AFO, air flow
obstruction; LLN, lower limit of normal.
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As for RV/TLC, change in RV measured by plethys-
mography correlated significantly with changes in radiolo-
gical GTS (R2=0.31, P=0.01), and this was similarly
attributable to changes occurring after 6 months
(R2=0.43, P<0.01), and not before (P=0.99)
There was no correlation between the change in QLF
(mL) from 2 to 18 months, and any of the following
plethysmography measures: change in TLC %pred.
(P=0.91), change in RV/TLC ratio (P=0.17) or change in
IC/TLC (P= 0.24).
Correlation of Physiology and
Radiological Measures at 18 Months
At 18 months, the FEV1/FVC correlated with radiological
GTS (R2 = 0.37, P=0.01) but not with LAA (emphysema
score: R2 = 0.17, P=0.07). There was also a correlation
between RV/TLC measured by plethysmography and GTS
on CT scan (R2 = 0.28, P=0.02), but not LAA
(R2 = 0.001, P= 0.89).
The TLC values obtained by plethysmography and CT
scan correlated well (R2 = 0.55, P < 0.01) at 18 months.
However, the correlation between RV/TLC measured by
plethysmography and by CT scan did not correlate signifi-
cantly (P=0.12). This was primarily due to the poorer
correlation between the measurement of RV with the two
techniques (R2=0.22, P=0.04), and is likely explained by
the difference in body position between plethysmography
and CT scans (ie, erect vs supine).
There was no correlation between fibrosis scores (QLF
(mL)) and either the TLC or the IC/TLC (P=0.12 and P=
0.93, respectively).
Discussion
The results of this 18-month prospective study of young,
immune-competent patients experiencing their first epi-
sode of pulmonary tuberculosis provides several insights
into the pathogenesis of lung function impairment and the
development of chronic lung disease during and following
treatment. Firstly, at one year after completing tuberculosis
Table 2 Lung Physiology Data at 2, 6 (Treatment Completion) and 18 Months (One Year After Treatment Completion)
n=43 Baseline 2 Months 6 Months 18 Months
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
FEV1 (L) 1.97 (1.50–2.76) 2.27 (1.68 −2.89) 2.39 (1.80–2.92) 2.52 (1.95–3.04)
FEV1 (%pred.) 0.59 (0.50–0.77) 0.73 (0.55–0.86) 0.75 (0.59–0.87) 0.79 (0.64–0.89)
FVC (L) 2.49 (1.90–3.02) 2.82 (2.22–3.44) 2.88 (2.30–3.54) 3.05 (2.54–3.59)
FVC (%pred.) 0.63 (0.54–0.73) 0.74 (0.57–0.84) 0.77 (0.62–0.87) 0.81 (0.66–0.88)
FEV1/FVC (%) 81.9 (75.2–88.1) 81.6 (76.2–89.0) 81.5 (75.3–88.2) 87.6 (75.4–89.9)
TLC (%pred.) – – 85.84 (72.40–93.76) 86.76 (78.17–100.12) 97.97 (83.96–110.69)
IC (%pred.) – – 82.05 (68.78–97.72) 83.67 (64.01–106.23) 88.16 (70.00–112.21)
FRC (%pred.) – – 89.53 (67.39–106.47) 97.15 (78.63–116.88) 105.43 (86.00–128.60)
RV (%pred.) – – 132.62 (97.73–156.62) 132.78 (102.01–164.17) 158.29 (111.66–210.65)
RV/TLC (%) – – 38.3 (32.5–46.8) 37.2 (32.5–47.9) 40.9 (35.4–50.0)
IC/TLC ratio – – 46.9 (41.3–53.3) 45.4 (35.1–50.8) 42.5 (36.7–46.5)
DLco (%pred.)a – – 66.98 (51.42–76.46) 61.68 (52.29–73.48) 65.31 (52.33–77.05)
DLco/VA (%pred.) – – 92.13 (83.73–103.02) 89.44 (80.32–101.20) 90.99 (75.67–100.35)
Six-minute walk distance (m) 510 (465–545) 510 (480–555) 529 (480–570) 520 (480–600)
SGRQ – Total Score
Mean (SD) - - - - 6.7 (11.0) 2.9 (9.9)
Median (IQR) - - - - 1.0 (0.00–12.3) 0.00 (0.00–0.4)
SGRQ – Activity Score
Mean (SD) - - - - 14.0 (25.9) 3.5 (15.5)
Median (IQR) - - 0.0 (0.0–24.4) 0.0 (0.0–0.0)
Notes: Plethysmography and diffusing capacity were not performed prior to 2 months due to risk to staff. St. George’s Respiratory Questionnaire (SGRQ) was only
performed from 6 months, as it is only validated for chronic symptoms. aFor diffusing capacity measurements, n=42.
Abbreviations: IQR, interquartile range; SD, standard deviation; FEV1, forced vital capacity in 1 sec; FVC, forced vital capacity; TLC, total lung capacity; IC, inspiratory
capacity; FRC, functional residual capacity; RV, residual volume; DLco, diffusing capacity for carbon monoxide; VA, alveolar volume; L, liters; %pred., percentage of
predicted; m, meters; SGRQ, St. George’s Respiratory Questionnaire.
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treatment three quarters of patients had at least one type of
lung abnormality as defined in this study. The most com-
mon abnormality at 18 months (in 33 of 42 patients;
78.6% of the cohort) was reduced diffusing capacity for
carbon monoxide. This was most commonly associated
with evidence of gas trapping (in 14 of 33 patients), con-
firmed on quantitative CT. Seven patients (16.3%) also had
evidence of chronic airflow obstruction (FEV1/FVC below
the LLN). Restriction was detected in 8 subjects with
reduced DLco, most of whom had no evidence of gas
trapping or airflow obstruction.
Secondly, the changes in lung volumes progressed in
the year after completion of anti-tuberculous treatment,
Figure 2 Median lung volumes measured by plethysmography at 2 (Visit 2), 6 (Visit
3, treatment completion) and 18 months (Visit 5).
Abbreviations: TLC, total lung capacity; IC, inspiratory capacity; FRC, functional
residual capacity; RV, residual volume. Figure 3 Venn diagram presenting in approximate proportions the number of
patients with single and combinations of lung function abnormalities one year
after completion of TB treatment (Visit 5): Airflow obstruction, gas trapping,
restriction, and low diffusing capacity. Airflow obstruction was defined using the
FEV1/FVC < lower limit of normal definition; restriction was defined as total lung
capacity (TLC) less than 80% predicted; gas trapping on plethysmography was
defined as a residual volume (RV) to TLC ratio (RV/TLC) of greater than 45%;
and a low DLco (corrected for haemoglobin) was defined as values of less than 80%
predicted.
Table 3 Quantitative Computed Tomography Values for Subjects with Scans Performed at 2, 6 (Treatment Completion) and 18
Months (One Year After Treatment Completion)









Median (IQR) Median (IQR) Median (IQR) P-valuec P-valuec P-valuec
TLC (L) 3.91 (3.14–4.44) 4.01 (3.39–4.57) 4.06 (3.46–4.69) 0.01 0.99 0.16
RV (L) 1.89 (1.58–2.36) 1.79 (1.56–2.19) 1.96a (1.65–2.19) 0.41 0.86 0.77
LAA (%b) 9.07% (4.57–11.04) 8.76% (6.78–11.63) 9.84% (7.75–14.45) 0.20 0.11 0.02
GTS (%b) 5.26% (2.79–9.16) 6.85% (4.23–10.98) 7.13%a (4.79–15.87) 0.19 0.04 0.02
QLF (%) 2.15% (1.31–3.41) 1.14% (0.72–1.67) 0.76% (0.57–1.55) <0.01 0.11 <0.01
QLF (mL) 84.67 (63.50–139.12) 38.30 (31.51–69.51) 30.48 (21.85–72.13) <0.01 0.07 <0.01
Notes: an=19. bPercentage of total lung volume. cP-value for paired Wilcoxon test.
Abbreviations: TLC, total lung capacity; RV, residual volume; LAA, low-attenuation areas on inspiratory scan (ie,<-950HU, emphysema score); GTS, gas-trapping score on
expiratory scan (ie, <-856HU); QLF, quantity of lung fibrosis; L, litres; mL, milliliters.
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presumably as a consequence of gas trapping rather than
emphysema. The increase in TLC one year after treatment
completion was largely due to a large increase in RV that
was not associated with an increase in IC. The CT imaging
confirmed that this increase in RV/TLC ratio correlated
more closely with radiological gas-trapping scores, than
with either emphysema or fibrosis scores. No correlation
was found between the fibrosis scores and any physiolo-
gical parameter, including TLC and IC/TLC. Together,
these findings suggest that the physiological gas trapping
is independent of emphysema, and may point to develop-
ing airflow limitation at the level of small airways. This
hypothesis is supported by lung images in individual
patients showing gas trapping on expiratory lung scans
one year after treatment, in spite of good resolution of
tuberculous pulmonary infiltrates (Figure 4). This explana-
tion is plausible given the extensive bronchiolar involve-
ment seen in more than 90% of patients with active
tuberculosis disease.11 The mechanisms responsible for
the consistently observed finding of reduced DLCO is less
clear, but potential involvement of vasculature within the
bronchovascular bundle in and around small airways is
one potential mechanism.15
Several large multi-centre studies and systematic
reviews have demonstrated the association of previous
tuberculosis and spirometric abnormalities.3–6,13,14,19,20
However, these and several smaller studies have been
performed without the use of plethysmography or quanti-
tative imaging. In this present study, we found spirometry
to be relatively insensitive in identifying post-tuberculosis
physiological abnormalities; almost twice as many patients
had plethysmographic evidence of gas trapping as com-
pared with spirometry, and almost 80% had a reduction in
diffusing capacity.
Our study has a number of strengths, these include its
prospective nature and the enrollment of a young popula-
tion without previous episodes of PTB, and without known
chronic respiratory or cardiac diseases, or recognized
impaired immune-incompetency. All PTB infections were
drug-sensitive and only those who completed treatment
and follow-up were included in analysis. Smoking
although not an exclusion criterion, was light (median
3.0 pack-years in those who smoked). It is thus reasonable
to assume, that despite the small sample size, the majority






2 months (Visit 2)
Inspiration
B
18 months (Visit 5) 
Inspiration Expiration
Figure 4 Inspiratory and expiratory, axial and coronal computed tomography images for a 20-year-old female, after 2 months of tuberculosis treatment (Visit 2) (A), and
1 year after treatment completion (Visit 5) (B). Resolution of infiltrates of tuberculosis and improvement in inspiratory lung volumes was found. However, areas of gas
trapping can be seen on the Visit 5 expiratory scan which were not present at 2 months, and are particularly prominent in regions where infiltrates of tuberculosis have
resolved.
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However, there are also a number of weaknesses,
which include its small size with the potential for selection
bias, loss of six patients in follow-up, and significant but
small correlations. The size of the study may have been
underpowered to assess smaller effect of potential co-
factors (eg, smoking). Further, in order to limit radiation
exposures, timepoints for CT imaging were varied to cap-
ture different stages of treatment and follow-up. Finally,
owing to potential infection risk, diffusing capacity and
body plethysmography were not performed at the baseline
visit. However, in spite of these limitations, statistically
significant trends were observed.
Conclusions
This young, previously healthy, adult population, demon-
strated a significant burden of airflow obstruction (one in
six) and residual chronic changes one year after the first
episode of treated tuberculosis. The residual disease bur-
den was underestimated by spirometry. Gas trapping (in
one third) and reduced DLco (in three quarters) were more
common than restriction (one in five). The RV and RV/
TLC continued to increase in the year after treatment
completion and correlated best with radiological gas trap-
ping. This is consistent with the hypothesis of residual and
evolving obstructive changes in the small airways after
tuberculosis.
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